Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23

Become a member
  1. OncologyPRO
  2. ESMO Videos
  3. Endocrine Cancer Videos

Cabozantinib versus Placebo for Advanced Neuroendocrine Tumours After Progression on Prior Therapy

Breaking Science in Endocrine Cancer Video Series

Login to get immediate access to this content.

Login

Speaker: Jennifer Chan, USA

Abstract discussed:

  • 1141O - Cabozantinib Versus Placebo for Advanced Neuroendocrine Tumors (NET) after Progression on Prior Therapy (CABINET Trial/Alliance A021602): Updated Results Including Progression Free-Survival (PFS) by Blinded Independent Central Review (BICR) and Subgroup Analyses: Watch the presentation from ESMO 2024 now

The speakers and studies featured in this video series were selected independently by ESMO.

Published October 2024

Related Videos

Screenshot Ramon SALAZAR
Screenshot Nicolas PENEL
Screenshot Hans Gelderblom
Screenshot Alexander DRILLON

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings

  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.